Cargando…

Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy

Investigation of neuroimmune interactions is one of the most developing areas in the study of multiple sclerosis pathogenesis. Recent evidence suggests the possibility of modulating neuroinflammation by targeting biogenic amine receptors. It has been shown that selective serotonin reuptake inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melnikov, Mikhail, Kasatkin, Dmitriy, Lopatina, Anna, Spirin, Nikolay, Boyko, Alexey, Pashenkov, Mikhail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355384/ https://www.ncbi.nlm.nih.gov/pubmed/35937048 http://dx.doi.org/10.3389/fneur.2022.920408

Ejemplares similares

The Role of D(2)-like Dopaminergic Receptor in Dopamine-mediated Modulation of Th17-cells in Multiple Sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2022)

The Dual Role of the β(2)-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2022)

Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?
por: Melnikov, Mikhail, et al.
Publicado: (2021)

Th17-cells in depression: Implication in multiple sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2022)

Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies
por: Boyko, Alexey, et al.
Publicado: (2020)

In Silico Drug Repurposing in Multiple Sclerosis Using scRNA-Seq Data
por: Shevtsov, Andrey, et al.
Publicado: (2023)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis
por: Melnikov, Mikhail, et al.
Publicado: (2020)

Central Neuropathic Pain and Profiles of Quantitative Electroencephalography in Multiple Sclerosis Patients
por: Krupina, Nataliya A., et al.
Publicado: (2020)

Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis
por: Dubchenko, Ekaterina, et al.
Publicado: (2020)

Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review
por: Capone, Fioravante, et al.
Publicado: (2022)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

Repurposing Histaminergic Drugs in Multiple Sclerosis
por: Amadio, Susanna, et al.
Publicado: (2022)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

The Broad Concept of “Spasticity-Plus Syndrome” in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms
por: Fernández, Óscar, et al.
Publicado: (2020)

Serotonergic Antidepressants and Risk for Traumatic Intracranial Bleeding
por: Isokuortti, Harri, et al.
Publicado: (2021)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
por: Leßmann, Volkmar, et al.
Publicado: (2023)

Multiple sclerosis and exercise—A disease-modifying intervention of mice or men?
por: Martin, Sarah-Jane, et al.
Publicado: (2023)

Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
por: Simoens, Steven
Publicado: (2022)

Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
por: Boziki, Marina Kleopatra, et al.
Publicado: (2020)

Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
por: Jayaraman, Sundararajan, et al.
Publicado: (2022)

Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients
por: Imamura, Keiko, et al.
Publicado: (2019)

Disease Activity and Progression of Disability in Multiple Sclerosis Patients Aged Over 50 With or Without Disease-Modifying Drug Treatment: A Retrospective Cohort Study
por: Kondo, Akihiro, et al.
Publicado: (2023)

Comorbidity in Multiple Sclerosis
por: Magyari, Melinda, et al.
Publicado: (2020)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
por: Claflin, Suzi B., et al.
Publicado: (2019)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

New Onset Multiple Sclerosis Post-COVID-19 Vaccination and Correlation With Possible Predictors in a Case-Control Study
por: Alluqmani, Majed
Publicado: (2023)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies
por: Bridge, Francesca, et al.
Publicado: (2023)

The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review
por: Kania, Karolina, et al.
Publicado: (2023)

Vaccination and Multiple Sclerosis – Current Situation
por: Boyko, A. N., et al.
Publicado: (2022)

A Brief Overview on BDNF-Trk Pathway in the Nervous System: A Potential Biomarker or Possible Target in Treatment of Multiple Sclerosis?
por: Schirò, Giuseppe, et al.
Publicado: (2022)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Editorial: Cognition in Multiple Sclerosis
por: Cortese, Rosa, et al.
Publicado: (2021)

Impact of Andropause on Multiple Sclerosis
por: Ysrraelit, Maria C., et al.
Publicado: (2021)

Therapeutic Advances in Multiple Sclerosis
por: Yang, Jennifer H., et al.
Publicado: (2022)

Editorial: Preventing multiple sclerosis
por: Dobson, Ruth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vbpf4bl981o3a3hikqk8ha87bg